An integrated map of HIV genome-wide variation from a population perspective

Retrovirology

Volumn 12, Issue 1, 2015, Pages

  Li, Guangdi ^a,b   Piampongsant, Supinya ^b   Faria, Rodrigues N ^c   Voet, Arnout ^d   Pineda Peña, Andrea Clemencia ^b,e   Khouri, Ricardo ^b,f   Lemey, Philippe ^b   Vandamme, Anne Mieke ^b,g   Theys, Kristof ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d RIKEN   (Japan)

^e UNIVERSIDAD DEL ROSARIO   (Colombia)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Conservation; Genomic diversity; HIV genome; HIV inter and inter clade genetic diversity; HIV phylogenetic tree; HIV human protein interaction; Peptide inhibitor; Protein intrinsic disorder; Protein multimerization; Selective pressure

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE; NUCLEOCAPSID PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VPR PROTEIN;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLADISTICS; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; OPEN READING FRAME; PHYLOGENY; PROMOTER REGION; PROTEIN MULTIMERIZATION; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRUS PARTICLE; DNA SEQUENCE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIROLOGY; VIRUS GENOME;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MIRIDAE;

GENETIC VARIATION; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; SEQUENCE ANALYSIS, DNA;

EID: 84928747332     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-015-0148-6     Document Type: Article

References (65)

1. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 2012;18:182-92.
2. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296:2354-60.
3. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem. 1998;67:1-25.
4. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012;10:279-90.
5. Acosta EG, Kumar A, Bartenschlager R. Revisiting dengue virus-host cell interaction: new insights into molecular and cellular virology. Adv Virus Res. 2014;88:1-109.
6. Perry CM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild(R)): a review of its use in the management of HIV-1 infection in adults. Drugs. 2014;74:75-97.
7. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010;85:91-100.
8. Fauci AS, Folkers GK, Dieffenbach CW. HIV-AIDS: much accomplished, much to do. Nat Immunol. 2013;14:1104-7.
9. Li G, Verheyen J, Rhee SY, Voet A, Vandamme AM, Theys K. Functional conservation of HIV-1 gag: implications for rational drug design. Retrovirology. 2013;10:126.
10. Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev. 2013;254:295-304.
11. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011;17:366-71.
12. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490:417-20.
13. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol. 2007;5:141-51.
14. Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, Zhao H, et al. Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol. 2011;85:7523-34.
15. Rousseau CM, Birditt BA, McKay AR, Stoddard JN, Lee TC, McLaughlin S, et al. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods. 2006;136:118-25.
16. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, et al. Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol. 2009;83:1845-55.
17. Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, Sanders-Buell E, et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol. 2005;79:6089-101.
18. Fernandez-Garcia A, Cuevas MT, Munoz-Nieto M, Ocampo A, Pinilla M, Garcia V, et al. Development of a panel of well-characterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. AIDS Res Hum Retroviruses. 2009;25:93-102.
19. Kousiappa I, Van De Vijver DA, Kostrikis LG. Near full-length genetic analysis of HIV sequences derived from Cyprus: evidence of a highly polyphyletic and evolving infection. AIDS Res Hum Retroviruses. 2009;25:727-40.
20. Sanabani SS, Pessoa R, Soares de Oliveira AC, Martinez VP, Giret MT, de Menezes Succi RC, et al. Variability of HIV-1 genomes among children and adolescents from Sao Paulo, Brazil. PLoS One. 2013;8:e62552.
21. Fernandez-Garcia A, Revilla A, Vazquez-de Parga E, Vinogradova A, Rakhmanova A, Karamov E, et al. The analysis of near full-length genome sequences of HIV type 1 subtype A viruses from Russia supports the monophyly of major intrasubtype clusters. AIDS Res Hum Retroviruses. 2012;28:1340-3.
22. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 2012;8:e1002529.
23. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987;326:662-9.
24. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58:19-42.
25. van der Kuyl AC, Berkhout B. The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology. 2012;9:92.
26. Snoeck J, Fellay J, Bartha I, Douek DC, Telenti A. Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints. Retrovirology. 2011;8:87.
27. Mayrose I, Stern A, Burdelova EO, Sabo Y, Laham-Karam N, Zamostiano R, et al. Synonymous site conservation in the HIV-1 genome. BMC Evol Biol. 2013;13:164.
28. Santoro MM, Perno CF. HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol. 2013;2013:481314.
29. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Isolation W-UNfH, Characterisation: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011;25:679-89.
30. Xue B, Mizianty MJ, Kurgan L, Uversky VN. Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. Cell Mol Life Sci. 2012;69:1211-59.
31. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. Engl J Med. 2012;366:1275-86.
32. Boons E, Li G, Vanstreels E, Vercruysse T, Pannecouque C, Vandamme A-M, et al. A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. Antiviral Research. 2014;112:91-102.
33. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet. 2004;5:52-61.
34. Falkowski PG, Fenchel T, Delong EF. The microbial engines that drive Earth's biogeochemical cycles. Science. 2008;320:1034-9.
35. Dunwell JM, Culham A, Carter CE, Sosa-Aguirre CR, Goodenough PW. Evolution of functional diversity in the cupin superfamily. Trends Biochem Sci. 2001;26:740-6.
36. Buck PM, Kumar S, Singh SK. On the role of aggregation prone regions in protein evolution, stability, and enzymatic catalysis: insights from diverse analyses. PLoS Comput Biol. 2013;9:e1003291.
37. Li G, Theys K, Verheyen J, Pineda-Pena A, Khouri R, Piampongsant S, et al. A new ensemble coevolution system for detecting HIV-1 protein coevolution. Biol Direct. 2015;10:1.
38. Zolla-Pazner S, Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol. 2010;10:527-35.
39. Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, et al. Global landscape of HIV-human protein complexes. Nature. 2012;481:365-70.
40. Burnett JC, Zaia JA, Rossi JJ. Creating genetic resistance to HIV. Curr Opin Immunol. 2012;24:625-32.
41. He Y. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion. Curr Pharm Des. 2013;19:1800-9.
42. Roberts KE, Cushing PR, Boisguerin P, Madden DR, Donald BR. Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity. PLoS Comput Biol. 2012;8:e1002477.
43. Durrant JD, McCammon JA. Molecular dynamics simulations and drug discovery. BMC Biol. 2011;9:71.
44. Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem. 2005;280:11259-73.
45. Rolland M, Nickle DC, Mullins JI. HIV-1 group M conserved elements vaccine. PLoS Pathog. 2007;3:e157.
46. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013;13:693-701.
47. Li G, Verheyen J, Theys K, Piampongsant S, Van Laethem K, Vandamme AM. HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes. Retrovirology. 2014;11:79.
48. Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337-48.
49. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2015;42:e144.
50. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792-7.
51. Gouy M, Guindon S, Gascuel O. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol. 2010;27:221-4.
52. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. Nature. 1996;381:272.
53. Pinney JW, Dickerson JE, Fu W, Sanders-Beer BE, Ptak RG, Robertson DL. HIV-host interactions: a map of viral perturbation of the host system. AIDS. 2009;23:549-54.
54. Llano A, Frahm N, Brander C. How to optimally define optimal cytotoxic T lymphocyte epitopes in HIV infection. HIV Mol Immunol. 2009;2009:3-24.
55. Buchan DW, Ward SM, Lobley AE, Nugent TC, Bryson K, Jones DT. Protein annotation and modelling servers at University College London. Nucleic Acids Res. 2010;38:W563-8.
56. Klose DP, Wallace BA, Janes RW. 2Struc: the secondary structure server. Bioinformatics. 2010;26:2624-5.
57. Ishida T, Kinoshita K. Prediction of disordered regions in proteins based on the meta approach. Bioinformatics. 2008;24:1344-8.
58. Peng K, Radivojac P, Vucetic S, Dunker AK, Obradovic Z. Length-dependent prediction of protein intrinsic disorder. BMC Bioinformatics. 2006;7:208.
59. Deng X, Eickholt J, Cheng J. PreDisorder: ab initio sequence-based prediction of protein disordered regions. BMC Bioinformatics. 2009;10:436.
60. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605-12.
61. Levy ED. A simple definition of structural regions in proteins and its use in analyzing interface evolution. J Mol Biol. 2010;403:660-70.
62. Price MN, Dehal PS, Arkin AP. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5:e9490.
63. Pond SL, Frost SD, Muse SV. HyPhy: hypothesis testing using phylogenies. Bioinformatics. 2005;21:676-9.
64. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003;51:229-40.
65. Li G: HIV genome-wide diversity, interaction and coevolution. Doctoral thesis. University of Leuven, Faculty of medicine; 2014. (https://lirias.kuleuven.be/handle/123456789/460408 )